Extended-release naltrexone, treatment for alcohol dependence, improves quality-of-life measures

Dec 01, 2008

Most studies examining the impact of alcohol-dependence (AD) treatment on quality-of-life (QOL) have looked at psychosocial treatments. This study looked at the impact of pharmacotherapy on QOL, specifically, the effects of extended-release naltrexone (XR-NTX), a once-a-month injectable formulation for the treatment of AD. Results showed significant improvements in the QOL areas of mental health, social functioning, general health, and physical functioning.

Results will be published in the February 2009 issue of Alcoholism: Clinical & Experimental Research and are currently available at Early View.

"Alcohol dependence is a chronic and disabling disorder," said Helen M. Pettinati, professor of psychology in the department of psychiatry, and director of the division of treatment research at the University of Pennsylvania School of Medicine. "Heavy drinking is associated with broad impairments in health-related QOL, with the largest impact typically found for mental health and social functioning."

XR-NTX (Vivitrol™) is a once-a-month injectable formulation for AD treatment; its 380 mg dose has been FDA-approved since 2006. Daily oral NTX doses are also available, typically at 50 mg or 100 mg a day.

"If naltrexone is taken orally for 30 days, this translates to a total monthly dose of 1,500 mg or 3,000 mg," explained Pettinati, who is also corresponding author for the study. "When compared to the once-a-month 380 mg injectable dose approved by the FDA and the only dose available clinically, we can see what appears to be a hefty difference in the amount of naltrexone given over a month's period to a single individual when dosed daily versus injection. However, this 'lower' injectable dose does not appear to compromise efficacy, likely due to different and more efficient pharmacokinetic properties in the injectable formulation."

"The important issue is that if you can change people's drinking patterns, then you can also change people's QOL," observed Allen Zweben, professor and associate dean for academic affairs and research in the school of social work at Columbia University. "Pharmacotherapy has never really looked at QOL vis-à-vis drinking behavior, but it would seem that the FDA is interested in learning how people's changes in drinking can have an impact on their QOL. There's an implication that QOL changes naturally, but in this study Dr. Pettinati actually looked at and measured QOL as a factor."

The researchers randomly assigned 624 AD patients (423 males, 201 females) to one of three groups during 24 weeks of treatment – XR-NTX at 380 mg (n=205), XR-NTX at 190 mg (n=210), or placebo (n=209) – in conjunction with a standardized psychosocial intervention. QOL was assessed using the Medical Outcomes Study 36-item short-form health survey, administered at baseline and then at four-week intervals during treatment.

"There were three main findings from this study," said Pettinati. "First, the AD sample showed impairments in QOL at pre-treatment compared with population norms, especially in mental-health and social functioning. Second, the XR-NTX 380 mg group showed meaningful and significant improvements compared to the placebo group in the QOL domains of mental health, social functioning, general health, and physical functioning. Third, reductions in drinking from pre-treatment levels were correlated with improvements in QOL."

"These finding reinforce the notion that treatment of alcoholism, whether it's by medication or psychotherapy, does work," said Zweben. "Medication thus becomes another option available to people. These findings also have implications for the issue of compliance, in that high compliance rates might have something to do with the fact that people improve their drinking as well as their QOL."

It is one thing to believe that treatment reduces drinking and that time abstinent from alcohol can lead to increased QOL improvements, said Pettinati. "It is another to show this connection with new pharmacotherapies as they become available to our AD patients."

"In terms of treatment options," said Zweben, "this study shows that pharmacotherapy may be very cost-effective. You don't necessarily have to have a separate intervention to deal with QOL issues – whether more intensive psychotherapy, or family therapy – you may be able to use one intervention to reduce drinking, and improve QOL. This study also has implications for using medication as an option. A lot of people don't believe medication has any basis in alcohol treatment, that 'alcohol is a chemical already so why are you prescribing more chemicals?' It is almost a bias against medications. These results help to reduce some of the stigma attached to using medication in terms of alcohol treatment."

Zweben noted, however, that these findings need to be replicated in future studies, that the patients examined were seeking treatment –differentiating them from the more general population of AD individuals – and that 35 to 37 percent of the patients did not receive all six injections.

Source: Alcoholism: Clinical & Experimental Research

Explore further: What to do with kidneys from older deceased donors?

add to favorites email to friend print save as pdf

Related Stories

Flocks of starlings ride the wave to escape

1 hour ago

Why does it seem as if a dark band ripples through a flock of European starlings that are steering clear of a falcon or a hawk? It all lies in the birds' ability to quickly and repeatedly dip to one side to avoid being attacked. ...

Blue Freedom uses power of flowing water to charge

2 hours ago

Good friends may decide to tell you something that is not true but nonetheless sustaining: Nothing is impossible. That was the case of Blue Freedom co-founder who asked his friend if it would be possible ...

Recommended for you

Obese British man in court fight for surgery

Jul 11, 2011

A British man weighing 22 stone (139 kilograms, 306 pounds) launched a court appeal Monday against a decision to refuse him state-funded obesity surgery because he is not fat enough.

2008 crisis spurred rise in suicides in Europe

Jul 08, 2011

The financial crisis that began to hit Europe in mid-2008 reversed a steady, years-long fall in suicides among people of working age, according to a letter published on Friday by The Lancet.

New food labels dished up to keep Europe healthy

Jul 06, 2011

A groundbreaking deal on compulsory new food labels Wednesday is set to give Europeans clear information on the nutritional and energy content of products, as well as country of origin.

Overweight men have poorer sperm count

Jul 04, 2011

Overweight or obese men, like their female counterparts, have a lower chance of becoming a parent, according to a comparison of sperm quality presented at a European fertility meeting Monday.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.